Skip to main content

Table 3 Utilization pattern of steroids and IL6-RAs in relation to ICU admission

From: Clinical characteristics and outcomes of critically ill mechanically ventilated COVID-19 patients receiving interleukin-6 receptor antagonists and corticosteroid therapy: a preliminary report from a multinational registry

Variables Value
Average daily dose (mg dexamethasone equivalent)a 7.50 [6, 14.1]
 Low steroid dose 496 (80.8)
 High steroid doseb 118 (19.2)
Day of steroid startc
 0 384 (55.6)
 1 102 (14.8)
 2 37 (5.4)
 3 22 (3.2)
 4 24 (3.5)
 After day 5 118 (17)
Tocilizumab 213 (78.3)
Tocilizumab number of dosesd
 1 180 (84.5)
 2 28 (13.1)
 3 5 (2.3)
Sarilumab 59 (21.7)
Sarilumab number of dosesd
 1 50 (84.7)
 2 9 (15.3)
Day of IL6-RAs start
 0 129 (39.5)
 1 55 (20.3)
 2 30 (11.1)
 3 21 (7.8)
 4 4 (1.5)
 After day 5 32 (11.8)
  1. Data presented as n (%) unless otherwise specified
  2. IL6-RAs interleukin-6 receptor antagonists
  3. aThe dose was available to 614 patients. The average daily dose of steroids was calculated by averaging the daily doses received by the patients during the ICU stay
  4. bHigh dose was defined as > 15 mg/day of dexamethasone or dexamethasone equivalent
  5. cThe proportion was calculated from the number of patients who received the steroids (n = 693)
  6. dThe proportion was calculated from the number of patients who received IL6-R antagonists intravenous formulation (n = 272)